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Abstract
Breast cancer is a complex disease resulting from a combination of genetic and environmental 
factors. Among environmental factors, body composition and intake of specific dietary 
components like total fat are associated with increased incidence of breast cancer and metastasis. 
We previously showed that mice fed a high-fat diet have shorter mammary cancer latency, 
increased tumor growth and more pulmonary metastases than mice fed a standard diet. Subsequent 
genetic analysis identified several modifiers of metastatic mammary cancer along with widespread 
interactions between cancer modifiers and dietary fat. To elucidate diet-dependent genetic 
modifiers of mammary cancer and metastasis risk, global gene expression profiles and copy 
number alterations from mammary cancers were measured and expression quantitative trait loci 
(eQTL) identified. Functional candidate genes that colocalized with previously detected metastasis 
modifiers were identified. Additional analyses, such as eQTL by dietary fat interaction analysis, 
causality and database evaluations, helped to further refine the candidate loci to produce an 
enriched list of genes potentially involved in the pathogenesis of metastatic mammary cancer.
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Breast cancer is the second most common cancer type and the third-leading cause of cancer-
related deaths of women living in the United States. It has been estimated that in 2009, 
nearly 200,000 women in the United States were diagnosed with some form of breast cancer 
and that over 40,000 died of this disease, typically from secondary metastasis. Breast cancer 
is a complex disease resulting from a combination of environmental and genetic factors. 
Although genetic factors altering predisposition to mammary cancer are starting to be 
elucidated with the identification of several familial risk factors [1–3], the overall genetic 
architecture remains largely unknown. This deficit is particularly evident at the intersection 
of genes and environmental factors like diet, which likely have the greatest impact on risk 
for metastatic mammary cancer.
Previously we generated an F2 intercross [4] between the M16i polygenic mouse model of 
obesity [5] and the FVB/NJ-TgN(MMTV-PyMT)634Mul (PyMT) mouse model of 
metastatic mammary cancer [6]. We found that animals fed a high-fat diet not only had 
decreased mammary cancer latency, but also increased tumor growth and pulmonary 
metastases relative to mice fed a standard mouse chow. Several modifier loci for metastatic 
mammary cancer were detected along with widespread modifier by dietary fat interactions 
[7]. Subsequently, subsets of mammary tumors from mice on standard and high fat diets 
were evaluated for differences in gene expression. Surprisingly, only five genes were 
differentially expressed between mice on the two dietary fat treatments [8]. Nonetheless, 
dietary fat was found to alter pulmonary metastasis of mammary cancers through both 
cancer autonomous and non-autonomous changes in gene expression [8].
In this report, the M16i x PyMT F2 population was analyzed to detect cancer expression 
quantitative trait loci (eQTL) and copy number alterations (CNA) regulating transcriptional 
networks associated with metastatic mammary cancer modifiers. With the aid of causality 
analysis and database evaluations, the candidate genes were further refined to produce an 




An F2 population (n = 615) was generated by crossing M16i, a polygenic obesity line [9], 
and FVB/NJ-TgN(MMTV-PyMT)634Mul (PyMT), a line transgenic for the Polyoma 
Middle T Oncoprotein that induces development of mammary cancers and subsequent 
pulmonary metastasis [6] (see [4] for full details of population development). F2 mice were 
randomly assigned, within litter, gender, and genotype (PyMT or no PyMT), to receive one 
of two synthetic purified diets at four weeks of age, either a high-fat diet (HFD; Research 
Diets D12451) containing 45% of total calories from fat, 20% from protein, and 35% from 
carbohydrates, or a matched-control-fat diet (MCD; Research Diets D12450B) containing 
10% of total calories from fat, 20% from protein, and 70% from carbohydrates. Mice were 
evaluated for body weight, body composition and metastatic mammary cancer phenotypes 
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as previously described [4, 7]. Axillary mammary tumors were harvested from 131 F2 
female PyMT carriers (HFD = 64 and MCD = 67) for microarray expression analysis.
Microarray analysis
For complete details refer to La Merrill et al [8]. Briefly, total RNA was isolated from 
axillary tumors using TRIzol (Invitrogen, Carlsbad, CA) and preprocessed for array 
hybridization using the Illumina® TotalPrep RNA Amplification kit (Ambion, Austin, TX). 
Expression profiles were generated using the Illumina Mouse 6 Sentrix arrays [10] 
(Illumina, San Diego, CA) and the resulting data were log transformed and normalized using 
the R-based evaluation program for Illumina expression data Lumi [11] prior to filtering at 
an Illumina detection score of 0.95 and above. Log transformed normalized data for all 
samples were run at a false discovery rate q- value < 0.05 in SAM software using two class-
unpaired analyses with 1000 permutations [12, 13].
Correlation analysis
Pearson correlations were generated between all significantly expressed genes and the 
metastatic cancer phenotypes previously measured in the F2 population [7]. The correlations 
were generated as three separate data sets: one for the whole population and the other two 
for animals on either the HFD or the MCD. All resulting p-values were adjusted with the 
FDR multiple comparisons test. Transcripts were then sorted by their strength of correlation 
within each metastasis phenotype.
Expression QTL (eQTL) analysis
eQTL were identified utilizing a customized R package, GaRT, for eQTL mapping in F2 
populations [http://gbi.agrsci.dk/~pso/GaRT]. The eQTL models were fit with the following 
effects: additive, dominance, breeding-replicate and diet. The resulting eQTL were classified 
in one of two categories: “cis” if they mapped within 10 cM of the physical location of the 
gene they represent, and “trans” if they mapped elsewhere [14]. The significance threshold 
for all eQTL was set at a likelihood ratio statistic of 16.1 (LOD: 3.5). All eQTL classified as 
cis-acting were evaluated for the presence of eQTL x diet interactions by running an 
additional model which included all the aforementioned effects in addition to an eQTL x 
diet interaction term. The sum-of-squares error and the degrees of freedom for the peak 
position for each eQTL in both the interaction and non-interaction models were then 
calculated and used to compute an F statistic.
Pathway evaluation
All eQTL were evaluated using Ingenuity Pathway Analysis (IPA; Ingenuity Systems Inc., 
Redwood City, CA). Using the IPA core analysis function, reports containing information 
regarding the function, regulation, known mutations, tissue expression patterns, cellular 
location, and disease implication were generated for all significant genes. IPA was also used 
to provide statistical rankings of biological functions based upon the number of genes from 
the analysis set that participate in particular function.
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Causality relationships between cis-acting eQTL and cancer phenotypes were evaluated 
using the R-based package eQTL-TF [15]. When estimating the relationships between cis-
acting eQTL and cancer phenotypes three models were considered. The causal model is 
where genetic alterations (G) result in changes in the expression of a cis-acting eQTL (C), 
which in turn result in modification of the phenotype (P); a reactive model is where variation 
in G directly impacts P, resulting in altered gene expression of C; and a independent model 
that evaluates whether variation in G can result in changes in both P and C independently.
Oncomine evaluation
All cis-eQTL colocalizing with previously detected metastatic QTL [7] were entered into the 
Oncomine database [16] to determine if the genes they represent had been previously linked 
to metastatic cancer in humans. Specifically, all human breast cancer prognosis datasets in 
Oncomine, which best represents the possibility of having a metastatic cancer phenotype, 
were evaluated at a p-value threshold of 0.01 for each gene. If a gene was identified in any 
of the datasets in the prognosis category, it was further evaluated to determine if its 
expression is positively (no metastasis, alive, no disease) or negatively (metastasis, dead, 
relapse) associated with the clinical phenotype.
Evaluation of CNA
Copy number alterations were evaluated using the NimbleGen mouse 385K whole genome 
tiling array (NimbleGen Systems, Inc. Madison, WI) with a median probe spacing of 5.7 kb, 
in a subset of the F2 females selected to represent the largest spectrum of cancer metastasis 
phenotype. This spectrum was achieved by selecting within each diet the 17 individuals with 
the highest number of observed pulmonary metastases and the 17 with the lowest number of 
observed pulmonary metastasis for a total of 68 individuals. RNA-free genomic DNA was 
extracted using the Puregene Tissue Core Kit (Qiagen, Minneapolis, MN) from the axillary 
mammary tumors (test) and tails (reference) of all 68 individuals. DNA samples were 
fragmented and fluorescently labeled with either cy-3 (tumor DNA) or cy-5 (tail DNA). The 
labeled tumor samples were pooled with their reference and co-hybridized to an array. 
Arrays were evaluated for relative fluorescence to determine the copy number profile across 
the genome for each individual using the NimbleScan software v2.3 (NimbleGen Systems, 
Inc. Madison, WI).
Resulting data were evaluated using SignalMap software (NimbleGen Systems, Inc. 
Madison, WI), to determine if patterns of CNA could be identified within the population. To 
provide common settings across the population, the log2 ratio scale was set at −2 and 2, 
while the track height was set at 120. Segments that deviated from 0.0 by ± 0.2–0.4 
indicated a single amplification or deletion. A segment that deviated from 0 by ± 0.4–0.6 
indicated a double amplification or deletion. If CNA were identified on chromosomes where 
cancer metastasis modifiers were previously detected (i.e. Chr 11), Proc Mixed in SAS (SAS 
Institute, Cary, NC) was used to determine whether significant associations were present 
between the copy number change and the phenotype used to map the modifier locus. The 
model evaluated included the fixed effects of diet and CNA, the interaction of diet x CNA, 
and the random effect of breeding replicate. If an association between the phenotype and 
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copy number change was detected, then cis-eQTL on the chromosome in question were also 
evaluated using the aforementioned Proc mixed model to determine if the gene expression 
levels were altered by the amplification or deletion.
Results
Correlation analysis
Correlations amongst gene expression and metastatic phenotypes were analyzed in a multi-
step process, beginning with the entire population regardless of diet. While many genes were 
weakly correlated with the metastatic phenotypes, no genes surpassed the significance 
threshold of p < 0.05 after adjustment for multiple testing. Given the substantial influence of 
the HFD upon the metastatic phenotype [7], we hypothesized that the correlations between 
gene expression and metastatic traits were obscured by the dietary treatment. As such, the 
data were separated according to diet group and reevaluated. No significant correlations 
between gene expression and metastatic virulence were detected in the animals only fed the 
HFD. However, when the correlations were evaluated in animals fed the MCD, 14 genes 
were found to have significant correlations with the metastatic phenotype (Table 1), 
including several that have been previously reported to be associated with metastatic 
progression (i.e. Col1a1 and Col5a1 [17]). IPA identified direct and indirect connections 
between several of the genes within this set and Trp53.
eQTL evaluation
Totals of 220 cis-acting eQTL and 890 trans-acting eQTL were detected (Figure 1 A and B). 
The cis-acting eQTL were found across all chromosomes. Chr 11 and 17 harboring the 
largest number, while Chr 2 and 16 had the fewest. Trans-acting eQTL were likewise 
distributed across all chromosomes with Chr 3, 8 and 19 containing the largest numbers. 
When averaged, the likelihood ratio (LRT) score for all cis-acting eQTL was 45.9 with 
individual LRT scores ranging from 16.2 to 197.1. The average LRT score for all trans-
acting eQTL was 23.9. If the trans-acting eQTL were evaluated as two separate groups, 
those mapping to the same chromosome (but not within 10 cM) as the actual gene they 
represent and those mapping to different chromosomes, the average LRT scores were 37.5 
and 19.0, respectively.
Comparing the locations of cis-acting eQTL with phenotypic cancer QTL previously 
reported for this population detected 76 candidates for the previously mapped metastasis 
modifiers and 95 candidates for tumor growth and latency modifiers. Candidate genes were 
further refined based on their proximity to the cancer modifiers. If genes only within 15 cM 
of the modifier peaks are considered, the number of candidates is reduced from 76 to 44 and 
from 95 to 33 for metastatic and tumor growth/latency modifiers, respectively (Tables 2 and 
3; Figures 2 and 3).
To investigate the functions of cis and trans-eQTL, the two separate gene lists were entered 
into IPA and evaluated with the core analysis function. Of the 220 cis-eQTL, 206 were 
found in the IPA database and of those, 117 were eligible for network and bio-function 
analysis (Table 4). The top bio-functions as indicated by IPA in the cis-acting dataset were 
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cellular movement and cancer, with genes in the cancer category occurring in many 
subgroups including apoptosis, tumor growth, migration, proliferation and invasion, along 
with categories representing a wide spectrum of specific cancer types. When the cellular 
movement group was expanded, the top functions were migration, invasion and localization. 
Additionally, genes were partitioned into networks based on the known or predicted 
interactions from the IPA database and ranked based on the number of candidate genes that 
appear within the dataset. Assessing the top functions of the highest ranked datasets revealed 
that many of these genes were involved in metabolism, cellular proliferation/death, and 
multiple processes of cancer.
Out of the 890 trans-acting eQTL, 808 were identified in the IPA database, and of those 515 
were network and bio-function eligible (Table 4). The top bio-functions represented in this 
dataset included carbohydrate metabolism, small molecule biochemistry and cancer. When 
the cancer bio-function category was expanded, the top functions of genes within this 
category were revealed to be involved in tumorigenesis, apoptosis and cell death. The 
expansion of the carbohydrate metabolism set identified genes involved in the metabolism 
of fructose-6-phosphate, glycosaminoglycan and UDP-N-acetylglucosamine. Networks with 
the highest scores in the trans-eQTL data shared similar functions to the top networks in the 
cis-eQTL, such as the processes involved in metabolism, small molecule biochemistry and 
cancer. DNA replication and repair, gene expression, and endocrine disorders were 
represented as well.
Diet interactions
When this population was previously evaluated for cancer modifiers [7], we found that the 
majority of QTL exhibited interactions with dietary fat levels. For example, the metastasis 
modifier previously identified on Chr 8 resulted from the presence of a significant QTL in 
mice fed the HFD but not the MCD [7]. As such it was possible that the cis- acting eQTL 
would also show dietary interactions and be useful as a filter to further narrow candidates 
within the cancer modifier confidence intervals. We found that ∼7% of the cis-eQTL had 
diet interactions (Table 5). Of the interactions detected, four resulted from differential allelic 
effects within the two diets (Slc43a3 on Chr 2, Basp1 on Chr 15, E4f1 on Chr 17 and Frmd8 
on Chr 19). All other eQTL by diet interactions resulted from the detection of a significant 
effect for animals fed one diet but not the other; the majority of significant effects were 
found in animals fed MCD.
Causality evaluation
To further refine the candidate gene list, the nature of the relationships between cis-eQTL 
and observed metastasis modifier loci was evaluated. If eQTL have a causal relationship 
with a metastasis modifier then they may in turn represent the actual underlying genetic 
modifier of the phenotype of interest [18]. The results revealed that few significant 
relationships existed between cis-eQTL and metastasis modifiers. In a several situations 
significant but weak independent associations were detected between eQTL and cancer 
modifiers, such as those observed for the Riken, Gtbp3, and Gcnt1 on Chr 1, 8 and 19, 
respectively (Table 6). One additional weak causal relationship was detected between H2afv 
and the metastasis modifier on Chr 11 (Table 6).
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Evaluation of the Oncomine database revealed that 22 of the 44 candidates for the metastasis 
modifiers have been previously reported in human breast cancer prognosis datasets (Table 
7). Of these, five were found to have an association between both increased and decreased 
gene expression and the clinical phenotype among the different datasets. Six of the 
candidates were found to have an increase in their expression associated with a better 
clinical outcome. In this category candidates whose orthologs had the greatest number of 
human studies supporting their association were Dusp4 on Chr 8 and Cxcl14 on Chr 13 with 
nine and five studies providing evidence, respectively. The final 11 candidates were found to 
have an increase in their expression that was associated with a poorer clinical prognosis. The 
candidate with the most compelling evidence in this group was H2afv on Chr 11 with seven 
studies supporting this link.
CNA evaluation
Although copy number alterations were detected in the mammary tumors (Figure 4), only 
four segments were shared among the tumors tested. The first was a 0.5 Mb segment on Chr 
8 at approximately 20 Mb. The second was a 9 Mb duplication on the distal end of Chr 11 
that was detected in 58% of the tumors tested. The third was on Chr 13 where a 1 Mb 
segment starting at 65 Mb was detected; 11% of the tumors having a duplication and 17% a 
deletion. The fourth region detected was a 0.25 Mb segment starting at 9.6 Mb on Chr 19 
with 8% of tumors having a duplication and 20% having a deletion. Additionally, the 
partitioning of samples based on dietary treatment did not reveal any significant associations 
between the diet consumed and CNA detection.
When copy number changes were evaluated to determine if they were associated with 
metastasis development, no relationship was identified within the regions on Chr 13 and 19, 
but significant associations were detected within the regions on Chr 8 (Figure 5 A) and 11 
(Figure 5 B). Individuals with a deletion of the Chr 8 region had significantly fewer 
pulmonary metastases compared to individuals with no CNA (p <.05), while individuals 
with a duplication of the region had almost a threefold increase in the number of metastasis 
detected when compared to individuals with no CNA (p <.05). Individuals with a 
duplication on Chr 11 had a significant reduction in metastasis development (p <.05). This 
evaluation was expanded to investigate whether the expression levels of the cis-eQTL on 
these two chromosomes were associated with the detected CNAs. One cis-eQTL, Ascc2 
located on Chr 11, was found to be associated with the CNA. A small but significant 
increase in expression of this gene was detected in animals that had a duplication on the 
distal end of Chr 11 (p <.05) (Figure 5 C).
Discussion
Estimates indicate that 60–70% of patients presenting with breast cancer have progressed to 
metastatic disease by the time of their diagnosis [19]. Consequently, the elucidation of the 
genetic and environmental factors influencing cancer progression to metastasis is essential 
for decreasing cancer mortality. Utilizing an F2 mouse population generated by crossing 
mice genetically predisposed to obesity and metastatic mammary cancer [4], several primary 
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tumor phenotypes were characterized such as tumor latency and growth and development of 
pulmonary metastasis [4]. In addition, we found that the consumption of a high fat diet not 
only contributes to increased tumor growth, but increased metastasis when compared to 
mice fed a normal level of dietary fat. These cancer phenotypes along with the genotypic 
data obtained from this F2 population facilitated the detection of multiple metastatic 
mammary cancer modifier loci, several of which exhibited modifier by diet interactions [4]. 
Unexpectedly, subsequent gene expression analyses within F2 tumors revealed that few 
genes were differentially expressed between the two dietary treatments [8]. However, when 
the individuals were segregated based on the level of metastasis, many more differentially 
expressed genes were identified [8]. Given the wide range of diet-dependent metastatic 
phenotypes and the clinical importance of the metastatic process, the current investigation 
into the genetic and transcriptional architecture of metastatic mammary cancer was 
undertaken.
A previous eQTL study limited to a select subset of genes that had been previously predicted 
to be important for metastasis was successful in identifying a pathway altered in metastatic 
mammary cancer [20]. Our whole genome eQTL analysis supported detection of cis and 
trans regulated eQTL present on all chromosomes. Several of the cis-acting eQTL mapped 
in close proximity to previously detected metastasis modifiers. cis-eQTL colocalizing with 
metastatic mammary cancer modifiers represent logical candidate genes [21, 22], such as 
reported for Rrp1b, a cis-eQTL that colocalized with a previously detected metastasis 
modifier, and was later predicted to be clinically important in metastatic disease [17]. 
Filtering the cis-eQTL based on their proximity to previously detected phenotypic QTL 
enabled the detection of 44 candidates colocalizing with metastatic modifier loci.
Given that modifier by diet interactions were previously identified in this F2 population [7] 
we anticipated that these interactions would be reflected in eQTL as well. However, only a 
small number of interactions were detected in the transcriptome mapping population. 
Additionally, the eQTL for which we detected diet interactions colocalizing with a cancer 
phenotype modifier, such as Gdi3 on Chr 13, and Frmd8 and Ms4a6c on Chr 19, resulted 
from significant eQTL effects in mice fed the MCD. The aforementioned results were not 
consistent with the interactions detected for the metastasis modifiers colocalizing with these 
eQTL, which resulted from significant eQTL effects in mice fed the HFD. Whereas the 
limited number of interactions was initially surprising given our previous findings, this 
result seems consistent with the lack of differentially expressed genes between the two 
dietary treatments [8].
The limited number of interactions detected may indicate that indirect effects of diet upon 
the cancers may have been responsible for the effects on cancer growth and metastasis 
previously observed. These effects may be mediated through transcriptional changes in 
another tissue such as the liver, known to respond metabolically to lipid consumption [23]. 
Links between hepatic expression of genes involved in the regulation of estrogenic 
compounds and breast cancer pathogenesis have been previously reported [24]. This appears 
to be supported by our findings that 36 of the 211 genes differentially expressed in the liver 
between the two dietary treatments were involved in cancer processes [8].
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Using causality testing, we detected one cis-eQTL, H2afv on Chr 11 coding for a protein 
that is a member of the histone H2a family, that was causally associated with a metastasis 
modifier. Histone modifications have been detected in human cancers [25] and can be used 
to provide insight into clinical outcomes [26]. Currently, very little information regarding 
the function of H2afv exists, but other members of the histone family H2A (H2AX) [27] and 
proteins they encode (Buforin IIb) [28] have been shown to be potent inhibitors of cancer. 
While a casual relationship between H2afv and a metastasis modifier on Chr 11 was 
detected, the overall limited number of observed associations (casual, reactive and 
independent) may be highlighting the complexity of mammary cancer metastasis.
Evaluation of the Oncomine database provided additional support for several of the 
candidates being involved in the development of metastatic mammary cancer. Analysis of 
this database yielded results that appear to support the link between H2afv and metastatic 
mammary cancer. Not only did we implicate H2afv as a candidate for the metastasis 
modifier on Chr 11 through causality analysis, the Oncomine evaluation supported a link 
between increased expression of this gene and a poorer clinical prognosis in humans. 
Another candidate, Dusp4, was implicated by Oncomine as a modifier of metastatic 
mammary cancer in humans as well. Dusp4, a member of the dual-specificity phosphatase 
family, has been previously implicated as a potential tumor suppressor in a variety of cancer 
types [29, 30] and may be potentially a strong candidate for the metastasis modifier 
identified on Chr 8.
One gene not identified in the Oncomine evaluation, which has been previously associated 
with metastatic mammary cancer in humans, is butyrophilin (Btn1a1) [31]. Btn1a1 was 
previously reported as being expressed significantly lower in primary cancers associated 
with metastatic versus those without metastasis [8]. Subsequent eQTL analysis provided 
evidence that Btn1a1 is a potential modifier of the metastasis modifier on Chr 13 [8].
We also analyzed mammary cancers for CNA to evaluate their impact on both metastasis 
development and the detection of cis-eQTL. All but one of the cis-eQTL acted 
independently of detected CNA. The expression of Ascc2, a gene physically located outside 
the genomic boundaries of a CNA on Chr 11, was associated with the adjacent CNA. It is 
possible that the CNA interval detected on Chr 11 contains an enhancer element that impacts 
the expression Ascc2 leading to the effect of the metastasis modifier on Chr 11. Ultimately, 
this highlights the importance of accounting for CNA in transcriptional studies, epically 
given the recent evidence suggesting that differences in CNA can alter the ability to detect 
eQTL [32].
In conclusion, this work is the first global eQTL analysis for metastatic mammary cancer, 
and demonstrates the utility of using transcriptome mapping to identify candidates for 
previously detected cancer modifiers. The use of causality testing provided insight into the 
relationship between the cis-eQTL detected for H2afv and the metastasis modifier on Chr 
11. The potential roles of H2afv and Dusp4 in metastatic mammary cancer were further 
supported by our evaluation of the Oncomine database. Aditionally, utilizing CNA analysis 
we detected a somatic alteration on chromosome 11 that was associated with increased 
expression of Ascc2, a gene for which a cis-eQTL was detected as a potential candidate for a 
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metastasis modifier on Chr 11. These findings provide additional insight into the genetic 
control of metastatic mammary cancer and possible targets for therapeutic interventions.
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The eQTL mapping results. A: The number of cis and trans-eQTL detected on each 
chromosome at the significance LRT threshold of 16.1. B: Mapping of expression QTL 
(eQTL). Physical gene positions on the microarray are plotted along the y-axis and the 
genetic locations of the QTL are plotted along the x-axis. eQTL along the cis diagonal map 
within 10 cM of the transcript that they represent. eQTL acting in trans map to a different 
chromosome than the transcript they represent. ^Master regulators are eQTL acting in cis 
that map to a region associated with many trans-acting eQTL.
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Metastatic QTL with colocalizing candidates. A: Cis-eQTL colocalizing with the metastatic 
locus on Chr 8. B: Cis-eQTL colocalizing with the metastatic locus on Chr 11. C: Cis-eQTL 
colocalizing with the metastatic locus on Chr 13. D: Cis-eQTL colocalizing with the 
metastatic locus on Chr 19.
Gordon et al. Page 15













Gordon et al. Page 16













Gordon et al. Page 17













Gordon et al. Page 18














Primary Tumor QTL with colocalizing candidates. A: Cis-eQTL colocalizing with the 
inguinal tumor growth locus on Chr 5. B: Cis-eQTL colocalizing with the tumor latency 
locus on Chr 7. C: Cis-eQTL colocalizing with the tumor latency locus on Chr 9. D: Cis-
eQTL colocalizing with the tumor latency locus on Chr 13. E: Cis-eQTL colocalizing with 
the tumor latency loci and total number of tumors at sacrifice loci on Chr 14. B: Cis-eQTL 
colocalizing with the axillary tumor growth locus on Chr 17.
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Examples of Copy Number Alteration (CNA) found in the F2 Population. A snapshot of the 
CNA found within the F2 population. Examples from three separate chromosomes (8, 9 and 
10) are shown.
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Evaluation of Copy Number Alteration (CNA). A: The impact of the Chr 8 CNA on the 
development of pulmonary metastasis. A duplication of this region was associated with a 
significant increase metastatic formation. B: The impact of the Chr 11 CNA on pulmonary 
metastasis development. The presence of an additional copy in this region was associated 
with a significant reduction in metastatic development. C: The impact of the Chr 11 CNA 
upon the expression of Ascc2. The presence of an additional copy in this region was 
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associated with a significant increase in the expression of Ascc2. *CNC: Copy number 
change. **All comparisons significant at p <.05.
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Table 4






cis-acting eQTL 206 117 Cancer (25) Cell death, Lipid metabolism, Small molecule biochemistry (22)
Cellular movement (10) Lipid metabolism, Small molecule biochemistry, cell morphology (20)
Gastrointestinal Disease (6) Genetic disorder, Neurological disease, Ophthalmic disease (14)
Cell cycle (9) Amino acid metabolism, Cancer, Carbohydrate metabolism (14)
trans-acting eQTL 808 515 Carbohydrate metabolism (14) Gene expression, DNA replication and repair, Endocrine system disorders (32)
Small molecule biochemistry (54) Drug metabolism, Cancer, Lipid metabolism (31)
Gene expression (21) Carbohydrate metabolism, Small molecule biochemistry, immune response (31)
Cancer (174) Gene expression, Cellular development, Nervous system development/function (29)
a
The number of candidates that were found in the IPA database
b
The number of candidates that had corresponding bio-function and network information in the IPA database
c
The top bio-functions as indicated by IPA . The number in () indicates how many of the candidates from the eligible list are involved in the 
function
d
The functions of the top networks as indicated by IPA. The number in () indicates how many of the candidates are in the particular network
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Table 5
Significant cis-eQTL by diet interactions
Symbol Chr Interactiona LRT
eQTL
peakb
E030013I19Rik 2 MCD 18.48 13.8
Dnajc1 2 MCD 23.40 7.8
Slc43a3 2 BD 42.13 46.8
Accs 2 HFD 22.93 55.8
Wfdc3 2 MCD 47.08 94.8
Prdx2 8 MCD 16.70 52.2
Bckdhb 9 MCD 54.01 46.2
Gdi3 13 MCD 129.35 4
D14Ertd449e 14 HFD 85.90 15.9
Basp1 15 BD 23.16 16.4
E4f1 17 BD 18.25 13.2
Notch4 17 MCD 26.02 14.2
Frmd8 19 BD 20.31 8.5
Ms4a6c 19 MCD 16.26 10.5
Pkd2l1 19 MCD 24.48 34.5
a
Interaction: (HFD) Significant effect in high-fat diet only; (MCD) Significant effect in the control diet only; (BD) Differential effects in high-fat 
and control diets
b
eQTL peak position in cM
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Table 7
Results from Oncomine database evaluation
Symbol Chr NF a EE positive b EE negative c
9330140K16Rik 1 x
Wwc2 8 1









Stk10 11 1 4
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The 44 candidates for the Metastatic QTL were evaluated in the Oncomine database to determine if a potential association between their expression 
and formation of metastasis has been previously reported in humans.
a
NF: An x indicates that the particular candidate was not found in the Oncomine human breast cancer prognosis datasets
b
EE positive: Indicates the number of studies reporting that increased expression is significantly associated with a positive (no metastasis, alive, 
disease free) clinical outcome.
c
EE negative: Indicates the number of studies reporting that increased expression is significantly associated with a negative (metastasis, dead, 
relapse) clinical outcome.
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